Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
1.
medrxiv; 2020.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2020.09.03.20183947

ABSTRACT

Background and aims: Immune dysregulation caused by SARS-CoV-2 infection is thought to play a pathogenic role in COVID-19. SARS-CoV-2 can infect a variety of host cells, including intestinal epithelial cells. We sought to characterize the role of the gastrointestinal immune system in the pathogenesis of the inflammatory response associated with COVID-19. Methods: We measured cytokines, inflammatory markers, viral RNA, microbiome composition and antibody responses in stool and serum samples from a prospectively enrolled cohort of 44 hospitalized COVID-19 patients. Results: SARS-CoV-2 RNA was detected in stool of 41% of patients and was found more frequently in patients with diarrhea than those without (16[44%] vs 5[19%], p=0.06). Patients who survived had lower median viral genome copies than those who did not (p=0.021). Compared to uninfected controls, COVID-19 patients had higher median fecal levels of IL-8 (166.5 vs 286.5 pg/mg; p=0.05) and lower levels of fecal IL-10 (678 vs 194 pg/mg; p<0.001) compared to uninfected controls. Stool IL-23 was higher in patients with more severe COVID-19 disease (223.8 vs 86.6 pg/mg; p=0.03) and we find evidence of intestinal virus-specific IgA responses, which was associated with more severe disease. Fecal cytokines and calprotectin levels were not correlated with gastrointestinal symptoms or with the level of virus detected. Conclusions: Although SARS-CoV-2 RNA was detectable in the stools of COVID-19 patients and select individuals had evidence for a specific mucosal IgA response, intestinal inflammation was limited, even in patients presenting with gastrointestinal symptoms.


Subject(s)
Signs and Symptoms, Digestive , Inflammation , Chronobiology Disorders , COVID-19 , Diarrhea
2.
biorxiv; 2020.
Preprint in English | bioRxiv | ID: ppzbmed-10.1101.2020.09.05.284224

ABSTRACT

Coronavirus Disease of 2019 (COVID-19) created dire consequences globally and triggered an enormous scientific effort from different domains. Resulting publications formed a gigantic domain-specific collection of text in which finding studies on a biomolecule of interest is quite challenging for general purpose search engines due to terminology-rich characteristics of the publications. Here, we present Vapur, an online COVID-19 search engine specifically designed for finding related protein - chemical pairs. Vapur is empowered with a biochemically related entities-oriented inverted index in order to group studies relevant to a biomolecule with respect to its related entities. The inverted index of Vapur is automatically created with a BioNLP pipeline and integrated with an online user interface. The online interface is designed for the smooth traversal of the current literature and is publicly available at https://tabilab.cmpe.boun.edu.tr/vapur/.


Subject(s)
COVID-19
3.
B. Joseph Elmunzer; Rebecca L. Spitzer; Lydia D. Foster; Ambreen A. Merchant; Eric F. Howard; Vaishali A. Patel; Mary K. West; Emad Qayad; Rosemary Nustas; Ali Zakaria; Marc S. Piper; Jason R. Taylor; Lujain Jaza; Nauzer Forbes; Millie Chau; Luis F. Lara; Georgios I. Papachristou; Michael L. Volk; Liam G. Hilson; Selena Zhou; Vladimir M. Kushnir; Alexandria M. Lenyo; Caroline G. McLeod; Sunil Amin; Gabriela N. Kuftinec; Dhiraj Yadav; Charlie Fox; Jennifer M. Kolb; Swati Pawa; Rishi Pawa; Andrew Canakis; Christopher Huang; Laith H. Jamil; Andrew M. Aneese; Benita K. Glamour; Zachary L. Smith; Katherine A. Hanley; Jordan Wood; Harsh K. Patel; Janak N. Shah; Emil Agarunov; Amrita Sethi; Evan L. Fogel; Gail McNulty; Abdul Haseeb; Judy A. Trieu; Rebekah E. Dixon; Jeong Yun Yang; Robin B. Mendelsohn; Delia Calo; Olga C. Aroniadis; Joseph F. LaComb; James M. Scheiman; Bryan G. Sauer; Duyen T. Dang; Cyrus R. Piraka; Eric D. Shah; Heiko Pohl; William M. Tierney; Stephanie Mitchell; Ashwinee Condon; Adrienne Lenhart; Kulwinder S. Dua; Vikram S. Kanagala; Ayesha Kamal; Vikesh K. Singh; Maria Ines Pinto-Sanchez; Joy M. Hutchinson; Richard S. Kwon; Sheryl J. Korsnes; Harminder Singh; Zahra Solati; Amar R. Deshpande; Don C. Rockey; Teldon B. Alford; Valerie Durkalski; Field F. Willingham; Patrick S. Yachimski; Darwin L. Conwell; Evan Mosier; Mohamed Azab; Anish Patel; James Buxbaum; Sachin Wani; Amitabh Chak; Amy E. Hosmer; Rajesh N. Keswani; Christopher J. DiMaio; Michael S. Bronze; Raman Muthusamy; Marcia I. Canto; V. Mihajlo Gjeorgjievski; Zaid Imam; Fadi Odish; Ahmed I. Edhi; Molly Orosey; Abhinav Tiwari; Soumil Patwardhan; Nicholas G. Brown; Anish A. Patel; Collins O. Ordiah; Ian P. Sloan; Lilian Cruz; Casey L. Koza; Uchechi Okafor; Thomas Hollander; Nancy Furey; Olga Reykhart; Natalia H. Zbib; John A. Damianos; James Esteban; Nick Hajidiacos; Melissa Saul; Melanie Mays; Gulsum Anderson; Kelley Wood; Laura Mathews; Galina Diakova; Molly Caisse; Lauren Wakefield; Haley Nitchie.
medrxiv; 2020.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2020.07.07.20143024

ABSTRACT

BackgroundThe prevalence and significance of digestive manifestations in COVID-19 remain uncertain. MethodsConsecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were manually abstracted from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19. ResultsA total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death. ConclusionsAmong patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common but the majority were mild and their presence was not associated with a more severe clinical course


Subject(s)
COVID-19
SELECTION OF CITATIONS
SEARCH DETAIL